Published in Encephale on June 01, 1999
Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Ther Adv Psychopharmacol (2015) 0.75
Relative Safety of Different Antidepressants for Treatment of Depression in Chronic Epileptic Animals Associated with Depression. J Epilepsy Res (2017) 0.75
Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice. Psychopharmacology (Berl) (2009) 0.75
Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl (2007) 2.12
Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system. Psychopharmacology (Berl) (1994) 1.12
Appropriate use of "knockout" mice as models of depression or models of testing the efficacy of antidepressants. Psychopharmacology (Berl) (2001) 1.12
3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev (1999) 1.04
Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) (1998) 1.04
Influence of age on behavioural response in the light/dark paradigm. Physiol Behav (1999) 0.98
The mouse light-dark paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry (2001) 0.98
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B Biomed Sci Appl (2001) 0.97
7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) (1997) 0.95
Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol (1997) 0.94
5-HT1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex. J Neurochem (2001) 0.94
Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.94
Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) (1999) 0.93
The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol (1996) 0.90
A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav (1998) 0.89
First report of mirtazapine-induced arthralgia. Eur Psychiatry (2001) 0.88
Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl) (2001) 0.87
The value of the reserpine test in psychopharmacology. Arzneimittelforschung (1983) 0.87
[Arthralgia associated with mirtazapine]. Therapie (2001) 0.87
Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT1B receptor knockout mice. J Neurochem (2003) 0.87
Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol (2003) 0.86
The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav (2000) 0.85
Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol (1991) 0.85
The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol (1996) 0.85
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res (2001) 0.85
Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res (2006) 0.85
Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl) (2001) 0.85
Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J Psychopharmacol (1998) 0.85
Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol (1999) 0.83
Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand (1997) 0.83
BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides (1999) 0.83
A typical mood stabilizers: a "typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl (2005) 0.82
Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav (1997) 0.81
Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav (2000) 0.81
[Characteristics of hypersensitivity syndrome to lamotrigine: review of one case reported in the Regional Center of Pharmacovigilance of Nantes]. Therapie (2002) 0.81
Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology (Berl) (1988) 0.81
[Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000]. Therapie (2002) 0.80
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl) (2001) 0.80
Theoretical study of haemoperfusion: drugs obeying a one-compartment pharmacokinetics model. Methods Find Exp Clin Pharmacol (1985) 0.80
Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatry Neurosci (1991) 0.80
[Isoniazid and rifampicin in the rabbit. Effect on hepatic microsomal enzyme activity]. J Pharmacol (1983) 0.80
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl) (1998) 0.80
Clonidine potentiates the effects of 5-HT1A, 5-HT1B and 5-HT2A/2C antagonists and 8-OH-DPAT in the mouse forced swimming test. Eur Neuropsychopharmacol (1998) 0.80
Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol Biochem Behav (1996) 0.79
[The new versus the old antidepressant drugs: a comparative study of their psychopharmacological profiles (author's transl)]. Encephale (1981) 0.79
The effect of lithium administration in animal models of depression: a short review. Fundam Clin Pharmacol (1999) 0.79
Quantitative analysis of serum methohexital by GLC using capillary column and nitrogen-selective detection. Fundam Clin Pharmacol (1988) 0.79
Are there gender differences in the temperature profile of mice after acute antidepressant administration and exposure to two animal models of depression? Behav Brain Res (2001) 0.79
Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in rats. Pharmacol Biochem Behav (1997) 0.79
Additive effect of lithium and clonidine with 5-HT1A agonists in the forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry (1994) 0.79
The additive effects of quinine on antidepressant drugs in the forced swimming test in mice. Psychopharmacology (Berl) (1995) 0.79
Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology (Berl) (2001) 0.79
Thiopurine methyl transferase activity: new extraction conditions for high-performance liquid chromatographic assay. J Chromatogr B Biomed Sci Appl (1999) 0.78
Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol (1986) 0.78
Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides (1994) 0.78
Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol (1997) 0.78
Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundam Clin Pharmacol (1997) 0.78
Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci (2000) 0.78
Pharmacology of new antipsychotic drugs: are they stabilizers of schizophrenic psychosis? Drug News Perspect (1998) 0.78
Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport (1995) 0.78
Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry (1992) 0.78
[5-HT1B serotonin receptors and antidepressant effects of selective serotonin reuptake inhibitors ]. C R Acad Sci III (2001) 0.78
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol (2006) 0.78
Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol (2001) 0.77
Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology (1994) 0.77
[Unexpected interactions of some psychotropic drugs with barbital and pentobarbital effects in mice (author's transl)]. J Pharmacol (1982) 0.77
Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.77
[Homozygote mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors]. C R Seances Soc Biol Fil (1998) 0.76
A rapid electron-capture gas chromatographic method for the quantification of fluvoxamine in brain tissue. J Pharmacol Toxicol Methods (1997) 0.76
Piracetam interactions with neuroleptics in psychopharmacological tests. Neuropsychobiology (1986) 0.76
5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. Eur J Pharmacol (1998) 0.76
Behavioral models in mice. Implication of the alpha noradrenergic system. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76
[Interaction between melilot and acenocoumarol? (Melilotruscus aculeatus)]. Therapie (2001) 0.76
Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors. Eur Neuropsychopharmacol (1999) 0.76
Effects of low-dose cholecystokinin on respiratory function in healthy volunteers. Eur Neuropsychopharmacol (2000) 0.76
Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology (Berl) (1994) 0.76
Interaction between 5-HT(1A) and 5-HT(1B) receptors: effects of 8-OH-DPAT-induced hypothermia in 5-HT(1B) receptor knockout mice. Eur J Pharmacol (2001) 0.76
CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides (2003) 0.76
Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry (1998) 0.76
Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides (1998) 0.76
[Methodology of preparing a list of educational objectives: example of application to pharmacology. Groupe Objectifs Pédagogiques de L'Association des Enseignants de Pharmacologie]. Therapie (1997) 0.75
Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice. Eur Neuropsychopharmacol (2001) 0.75
The cholecystokinin hypothesis of panic and anxiety disorders: a review. J Psychopharmacol (1992) 0.75
[On a new pharmacological action of antidepressants]. J Psychiatry Neurosci (1994) 0.75
[Mechanism of action of clonidine in the forced-swimming test in mice]. Encephale (1989) 0.75
Factors triggering abolishment of benzodiazepines effects in the Four-Plate Test--retest in mice. Eur Neuropsychopharmacol (2007) 0.75
[Blood concentrations of maprotiline in depressive patients]. Encephale (1989) 0.75
[Striatal hypersensitivity to neuroleptics. Therapeutic difficulties and medico-legal aspects]. Therapie (1989) 0.75
[Triazolam 0.25 mg versus loprazolam 1 mg in the treatment of common insomnia treated in general practice. Double-blind cross-over randomized trial]. Therapie (1989) 0.75
Comparative pharmacokinetic study of conventional and sustained-release viloxazine in normal volunteers. Neuropsychobiology (1989) 0.75
A barbital derivative as an atypical antidepressant drug in mice. Arzneimittelforschung (1987) 0.75
[Rhabdomyolysis during treatment with rabeprazole (Pariel), a proton pump inhibitor combined with domperidone (Peridys)]. Therapie (2003) 0.75
Rapid gas-chromatographic assay of bupivacaine in plasma. Fundam Clin Pharmacol (1987) 0.75
Is iprindole an indirect betamimetic drug? Neuropsychobiology (1988) 0.75
[Weaning of a dependence on amineptine by clonidine]. Therapie (1989) 0.75
Viloxazine as a betamimetic antidepressant drug. Neuropsychobiology (1987) 0.75
[Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach]. Therapie (1998) 0.75
Sensitive one-step extraction procedure for high-performance liquid chromatographic determination of viloxazine in human plasma. J Chromatogr (1990) 0.75
Effects of administration route on pharmacokinetics of aspirin in the rabbit. Methods Find Exp Clin Pharmacol (1988) 0.75
[Medicinal synergism]. Cah Odontostomatol Touraine (1979) 0.75